XKRX048530
Market cap129mUSD
Dec 24, Last price
5,680.00KRW
1D
-0.70%
1Q
-2.91%
Jan 2017
-62.88%
IPO
-61.75%
Name
iNtRON Biotechnology Inc
Chart & Performance
P/E
—
P/S
19.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.28%
Rev. gr., 5y
-14.17%
Revenues
9.59b
-31.57%
Net income
-9.70b
L
CFO
3.12b
-48.09%
Dividend
Dec 27, 2023100 KRW/sh
Earnings
Mar 11, 2025
Profile
iNtRON Biotechnology, Inc. develops biopharmaceuticals for the prevention and treatment of human diseases worldwide. It develops bacteriophage and endoricin drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 9,585,444 -31.57% | 14,006,978 -52.21% | 29,308,005 -35.49% | ||||||
Cost of revenue | 10,470,680 | 10,331,323 | 14,647,891 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (885,236) | 3,675,655 | 14,660,115 | ||||||
NOPBT Margin | 26.24% | 50.02% | |||||||
Operating Taxes | (1,141,478) | 2,606,859 | 846,806 | ||||||
Tax Rate | 70.92% | 5.78% | |||||||
NOPAT | 256,242 | 1,068,796 | 13,813,308 | ||||||
Net income | (9,695,412) -269.74% | 5,711,908 -41.28% | 9,728,024 -34.92% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (8,993,828) | ||||||||
BB yield | 3.07% | ||||||||
| Debt | |||||||||
Debt current | 144,615 | 30,985,122 | 29,627,350 | ||||||
Long-term debt | 661,204 | 572,746 | 16,128,405 | ||||||
Deferred revenue | 41,652 | 41,652 | 1,850,265 | ||||||
Other long-term liabilities | 710,457 | 666,882 | 783,731 | ||||||
Net debt | (69,161,727) | (86,440,316) | (78,618,814) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 3,117,611 | 6,005,660 | 16,555,493 | ||||||
CAPEX | (9,551,873) | (2,616,743) | (3,494,437) | ||||||
Cash from investing activities | 52,152,585 | (46,250,234) | (41,361,049) | ||||||
Cash from financing activities | (40,168,092) | (9,190,660) | 39,749,991 | ||||||
FCF | (6,088,109) | 3,710,762 | 16,368,949 | ||||||
| Balance | |||||||||
Cash | 57,184,011 | 108,220,484 | 113,496,667 | ||||||
Long term investments | 12,783,535 | 9,777,700 | 10,877,902 | ||||||
Excess cash | 69,488,274 | 117,297,835 | 122,909,169 | ||||||
Stockholders' equity | 65,748,438 | 36,163,161 | 30,086,444 | ||||||
Invested Capital | 32,140,809 | 101,998,067 | 118,323,371 | ||||||
ROIC | 0.38% | 0.97% | 14.22% | ||||||
ROCE | 2.63% | 9.87% | |||||||
| EV | |||||||||
Common stock shares outstanding | 33,191 | 36,024 | 34,680 | ||||||
Price | 8,780.00 8.00% | 8,130.00 -61.38% | 21,050.00 -24.42% | ||||||
Market cap | 291,418,174 -0.50% | 292,873,640 -59.88% | 730,016,652 -23.20% | ||||||
EV | 222,256,447 | 206,433,324 | 651,397,838 | ||||||
EBITDA | 1,026,428 | 5,242,471 | 16,196,622 | ||||||
EV/EBITDA | 216.53 | 39.38 | 40.22 | ||||||
Interest | 2,918,919 | 3,505,895 | 1,636,331 | ||||||
Interest/NOPBT | 95.38% | 11.16% | |||||||